References
Key articles
Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2017 Mar;119(3):371-80. Abstract
European Association of Urology. Guidelines on non-muscle-invasive bladder cancer. 2021 [internet publication].Full text
Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol. 2020 Aug;38(8):1895-904.Full text Abstract
American Urological Association. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO joint guideline. 2020 [internet publication].Full text
Fernández MI, Brausi M, Clark PE, et al. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2019 Jan;37(1):3-13. Abstract
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466-5. Abstract
Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013 Mar;63(3):462-72. Abstract
Reference articles
1. Brierley JD, Gospodarowicz MK, Wittekind C, eds. Union for International Cancer Control (UICC). TNM classification of malignant tumors. 8th ed. Chichester: Wiley-Blackwell; 2017.
2. Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016 Jul;70(1):106-19. Abstract
3. Mostofi FK, Sobin LH, Torloni H, et al. Histological typing of urinary bladder tumours. In: International classification of tumors. Number 10. Geneva, Switzerland: World Health Organization; 1973.Full text
4. Sauter G, Algaba F, Amin M, et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein JI, Sesterhenn I, eds. WHO classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.
5. Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2017 Mar;119(3):371-80. Abstract
6. European Association of Urology. Guidelines on non-muscle-invasive bladder cancer. 2021 [internet publication].Full text
7. MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothlial neoplasms. Eur Urol. 2007 Apr;51(4):889-97. Abstract
8. Colombel M, Soloway M, Akazac H, et al. Epidemiology, staging, grading, and risk stratification of bladder Cancer. Eur Urol Suppl. 2008 Oct;7(10):618-26.Full text
9. Cumberbatch MGK, Noon AP. Epidemiology, aetiology and screening of bladder cancer. Transl Androl Urol. 2019 Feb;8(1):5-11.Full text Abstract
10. Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol. 2020 Aug;38(8):1895-904.Full text Abstract
11. American Urological Association. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO joint guideline. 2020 [internet publication].Full text
12. Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017 Jan;71(1):96-108. Abstract
13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30.Full text Abstract
14. Wang Y, Chang Q, Li Y. Racial differences in urinary bladder cancer in the United States. Sci Rep. 2018 Aug 21;8(1):12521.Full text Abstract
15. Scosyrev E, Noyes K, Feng C, et al. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009 Jan 1;115(1):68-74.Full text Abstract
16. Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018 Dec;74(6):784-95. Abstract
17. Cumberbatch MG, Rota M, Catto JW, et al. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol. 2016 Sep;70(3):458-66. Abstract
18. Cumberbatch MG, Cox A, Teare D, et al. Contemporary occupational carcinogen exposure and bladder cancer: a systematic review and meta-analysis. JAMA Oncol. 2015 Dec;1(9):1282-90.Full text Abstract
19. Kaldor JM, Day NE, Kittelmann B, et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. Int J Cancer. 1995 Sep 27;63(1):1-6. Abstract
20. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1995 Apr 5;87(7):524-30. Abstract
21. Suriano F, Altobelli E, Sergi F, et al. Bladder cancer after radiotherapy for prostate cancer. Rev Urol. 2013;15(3):108-12.Full text Abstract
22. Wang M, Yang Y, Liao Z. Diabetes and cancer: epidemiological and biological links. World J Diabetes. 2020 Jun 15;11(6):227-38.Full text Abstract
23. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010 Jul;33(7):1674-85.Full text Abstract
24. Colmers IN, Bowker SL, Majumdar SR, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 2012 Sep 4;184(12):E675-83.Full text Abstract
25. Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016 Mar 30;352:i1541.Full text Abstract
26. Sui X, Lei L, Chen L, et al. Inflammatory microenvironment in the initiation and progression of bladder cancer. Oncotarget. 2017 Nov 3;8(54):93279-94.Full text Abstract
27. Alanee S, Alvarado-Cabrero I, Murugan P, et al. Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. World J Urol. 2019 Jan;37(1):107-14. Abstract
28. Fernández MI, Brausi M, Clark PE, et al. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2019 Jan;37(1):3-13. Abstract
29. Liow E, Tran B. Precision oncology in urothelial cancer. ESMO Open. 2020 Mar;5(suppl 1):e000616.Full text Abstract
30. Rozanski TA, Grossman HB. Recent developments in the pathophysiology of bladder cancer. Am J Radiol. 1994 Oct;163(4):789-92.Full text Abstract
31. Sidranski D, Frost P, Von Eschenback A, et al. Clonal origin of bladder cancer. N Engl J Med. 1992 Mar 12;326(11):737-40. Abstract
32. Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110-5.Full text Abstract
33. Rink M, Crivelli JJ, Shariat SF, et al. Smoking and bladder cancer: a systematic review of risk and outcomes. Eur Urol Focus. 2015 Aug;1(1):17-27. Abstract
34. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: bladder cancer [internet publication].Full text
35. Shariat SF, Lee R, Lowrance WT, et al. The effect of age on bladder cancer incidence, prognosis and therapy. Aging health. 2010 Oct;6(5):649-59.
36. Dobruch J, Daneshmand S, Fisch M, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016 Feb;69(2):300-10. Abstract
37. Nielsen M, Qaseem A; High Value Care Task Force of the American College of Physicians. Hematuria as a marker of occult urinary tract cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2016 Apr 5;164(7):488-97.Full text Abstract
38. Jubber I, Shariat SF, Conroy S, et al. Non-visible haematuria for the detection of bladder, upper tract, and kidney cancer: an updated systematic review and meta-analysis. Eur Urol. 2020 May;77(5):583-98. Abstract
39. Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006 Nov 1;107(9):2173-9.Full text Abstract
40. Shen P, Yang J, Wei W, et al. Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis. BJU Int. 2012 Sep;110(6 Pt B):E209-15. Abstract
41. Zheng C, Lv Y, Zhong Q, et al. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int. 2012 Dec;110(11 Pt B):E680-7.Full text Abstract
42. Lu YY, Chen JH, Liang JA, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2012 Sep;81(9):2411-6.Full text Abstract
43. Li S, Zeng XT, Ruan XL, et al. Simultaneous transurethral resection of bladder cancer and prostate may reduce recurrence rates: a systematic review and meta-analysis. Exp Ther Med. 2012 Oct;4(4):685-92.Full text Abstract
44. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J. 2008 Jun;2(3):212-21.Full text Abstract
45. Mohammed AA, El-Tanni H, El-Khatib HM, et al. Urinary bladder cancer: biomarkers and target therapy, new era for more attention. Oncol Rev. 2016 Dec 14;10(2):320.Full text Abstract
46. D'Costa JJ, Goldsmith JC, Wilson JS, et al. A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer. Bladder Cancer. 2016 Jul 27;2(3):301-17.Full text Abstract
47. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466-5. Abstract
48. Fernandez-Gomez J, Madero R, Solsona E, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol. 2011 Sep;60(3):423-30. Abstract
49. Soukup V, Čapoun O, Cohen D, et al. Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European Association of Urology non-muscle-invasive bladder cancer guidelines panel. Eur Urol Focus. 2020 May 15;6(3):479-89. Abstract
50. Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU guideline. J Urol. 2020 Oct;204(4):778-86.Full text Abstract
51. European Association of Urology. Guidelines on muscle-invasive and metastatic bladder cancer. 2021 [internet publication].Full text
52. Kamat AM, Bellmunt J, Galsky MD, et al. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 Aug 15;5(1):68.Full text Abstract
53. Leow JJ, Bedke J, Chamie K, et al. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J Urol. 2019 Jan;37(1):61-83. Abstract
54. Rhea LP, Mendez-Marti S, Kim D, et al. Role of immunotherapy in bladder cancer. Cancer Treat Res Commun. 2021;26:100296.Full text Abstract
55. Soria F, Mosca A, Gontero P. Drug strategies for bladder cancer in the elderly: is there promise for the future? Expert Opin Pharmacother. 2019 Aug;20(11):1387-96. Abstract
56. Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review. JAMA. 2020 Nov 17;324(19):1980-91. Abstract
57. Chou R, Selph S, Buckley DI, et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol. 2017 May;197(5):1189-99. Abstract
58. Lamm DL, Torti F. Bladder cancer, 1996. CA Cancer J Clin. 1996 Mar-Apr;46(2):93-112.Full text Abstract
59. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013 Mar;63(3):462-72. Abstract
60. Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol. 2020 May;203(5):902-9. Abstract
61. Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. J Urol. 2013 Mar;189(3):834-9. Abstract
62. Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2016 Feb;69(2):231-44. Abstract
63. Bosschieter J, Nieuwenhuijzen JA, Vis AN, et al. An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups. Urol Oncol. 2018 Sep;36(9):400.e7-400.e14. Abstract
64. Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002 May;41(5):523-31. Abstract
65. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol. 2002 Apr;167(4):1634-7. Abstract
66. Jakse G, Algaba F, Malmström PU, et al. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol. 2004 May;45(5):539-46. Abstract
67. Divrik T, Yildirim U, Eroğlu AS, et al. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol. 2006 Apr;175(4):1258-61. Abstract
68. Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol. 2007 Jan;177(1):75-9. Abstract
69. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000 Apr;163(4):1124-9. Abstract
70. Aziz A, May M, Burger M, et al. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. Eur Urol. 2014 Jul;66(1):156-63. Abstract
71. ClinicalTrials.gov. Study of pembrolizumab (MK-3475) in participants with high risk non-muscle invasive bladder cancer (MK-3475-057/KEYNOTE-057). 2021 [internet publication].Full text
72. Zhou L, Liang X, Zhang K. Assessment of the clinical efficacy of simultaneous transurethral resection of both bladder cancer and the prostate: a systematic review and meta-analysis. Aging Male. 2020 Dec;23(5):1182-93.Full text Abstract
73. Peress JA, Waterhouse K, Cole AT. Complications of partial cystectomy in patients with high grade bladder carcinoma. J Urol. 1977 Nov;118(5):761. Abstract
74. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018 Nov 15;379(20):1895-904.Full text Abstract
75. Hussein AA, May PR, Jing Z, et al. Outcomes of intracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol. 2018 May;199(5):1302-11. Abstract
76. American Urological Association. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. 2020 [internet publication].Full text
77. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28;349(9):859-66.Full text Abstract
78. Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004 Mar;45(3):297-303. Abstract
79. Advanced Bladder Cancer Meta-analysis Collaboration. Neo-adjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD005246.Full text Abstract
80. Gandaglia G, Popa I, Abdollah F, et al. The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study. Eur Urol. 2014 Sep;66(3):561-8. Abstract
81. Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist. 2016 Jun;21(6):708-15.Full text Abstract
82. Zargar H, Shah JB, van Rhijn BW, et al. Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy. J Urol. 2018 Jun;199(6):1452-8. Abstract
83. Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014 Jul;66(1):42-54.Full text Abstract
84. Chism DD. Urothelial carcinoma of the bladder and the rise of immunotherapy. J Natl Compr Canc Netw. 2017 Oct;15(10):1277-84. Abstract
85. Roche. Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer. Mar 2021 [internet publication].Full text
86. AstraZeneca. Voluntary withdrawal of Imfinzi indication in advanced bladder cancer in the US. Feb 2021 [internet publication].Full text
87. US Food and Drug Administration. FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy to treat urothelial cancer with low expression of PD-L1. Aug 2018 [internet publication].Full text
88. Suzman DL, Agrawal S, Ning YM, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist. 2019 Apr;24(4):563-9.Full text Abstract
89. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018 Feb 24;391(10122):748-57. Abstract
90. ClinicalTrials.gov. Study of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy alone in urothelial carcinoma (MK-3475-361/KEYNOTE-361). NCT02853305. May 2021 [internet publication].Full text
91. European Medicines Agency. EMA restricts use of Keytruda and Tecentriq in bladder cancer. Jun 2018 [internet publication].Full text
92. Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020 Sep 24;383(13):1218-30.Full text Abstract
93. Rao A, Patel MR. A review of avelumab in locally advanced and metastatic bladder cancer. Ther Adv Urol. 2019 Jan-Dec;11:1756287218823485.Full text Abstract
94. Merseburger AS, Apolo AB, Chowdhury S, et al. SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World J Urol. 2019 Jan;37(1):95-105. Abstract
95. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012 Apr 1;30(10):1107-13. Abstract
96. European Medicines Agency. Summary of opinion (post authorisation). Bavencio (avelumab). Dec 2020 [internet publication].Full text
97. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009 Jul 18;374(9685):239-49. Abstract
98. Carrion R, Seigne J. Surgical management of bladder carcinoma. Cancer Control. 2002Jul-Aug;9(4):284-92. Abstract
99. Siefker-Radtke A. Systemic chemotherapy options for metastatic bladder cancer. Expert Rev Anticancer Ther. 2006 Jun;6(6):877-85. Abstract
100. European Medicines Agency. Tecentriq: withdrawal of the application to change the marketing authorisation. 2021 [internet publication].Full text
101. Lopez-Beltran A, Cimadamore A, Blanca A, et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel). 2021 Jan 3;13(1):131.Full text Abstract
102. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021 Jun 3;384(22):2102-14. Abstract
103. Mollica V, Rizzo A, Montironi R, et al. Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma. Cancers (Basel). 2020 Jun 2;12(6):1449.Full text Abstract
104. Farina MS, Lundgren KT, Bellmunt J. Immunotherapy in urothelial cancer: recent results and future perspectives. Drugs. 2017 Jul;77(10):1077-89. Abstract
105. Petrylak DP, de Wit R, Chi KN, et al; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017 Nov 18;390(10109):2266-77. Abstract
106. Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):105-20.Full text Abstract
107. Al-Obaidy KI, Cheng L. Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder. J Clin Pathol. 2021 Mar 17 [Epub ahead of print]. Abstract
108. Vlachostergios PJ, Jakubowski CD, Niaz MJ, et al. Antibody-drug conjugates in bladder cancer. Bladder Cancer. 2018 Jul 30;4(3):247-59.Full text Abstract
109. Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019 Jul 25;381(4):338-48.Full text Abstract
110. Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2021 Feb;18(2):93-103. Abstract
111. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021 Mar 25;384(12):1125-35. Abstract
112. Faltas B, Goldenberg DM, Ocean AJ, et al. Sacituzumab govitecan, a novel antibody--drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016 Feb;14(1):e75-9.Full text Abstract
113. ClinicalTrials.gov. Phase II open label, study of IMMU-132 in metastatic urothelial cancer. Feb 2021 [internet publication].Full text
114. Kowalski M, Guindon J, Brazas L, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. J Urol. 2012 Nov;188(5):1712-8. Abstract
115. ClinicalTrials.gov. Vicinium treatment for subjects with non-muscle invasive bladder cancer previously treated with BCG. Jun 2021 [internet publication].Full text
116. ClinicalTrials.gov. Dose escalation, expansion study of vofatamab (B-701) in treatment of locally advanced or metastatic urothelial cell carcinoma (FIERCE-21). Mar 2020 [internet publication].Full text
117. FDA. Manufacturing issues remain for Indevus' Valstar. Jan 2008 [internet publication].Full text
118. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol. 2000 Mar;163(3):761-7. Abstract
119. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003 Dec 1;21(23):4270-6. Abstract
120. Witjes JA, Hendricksen K, Gofrit O, et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009 Jun;27(3):319-24.Full text Abstract
121. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bladder cancer [internet publication].Full text
122. Lamm DL, Riggs DR, Traynelis CT, et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder. J Urol. 1995 May;153(5):1444-50. Abstract
123. Lamm D, Colombel M, Persad R, et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol. 2008 Oct 1;7(10):651-66.
124. Gudjonsson S, Adell L, Merdasa F, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009 Apr;55(4):773-80. Abstract
125. Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009 Aug;56(2):247-56. Abstract
126. Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997 Jul;158(1):62-7. Abstract
127. Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guérin. Eur Urol. 2016 Jan;69(1):60-9. Abstract
128. Golijanin DJ, Kakiashvili D, Madeb RR, et al. Chemoprevention of bladder cancer. World J Urol. 2006 Nov;24(5):445-72. Abstract
129. Picozzi S, Ricci C, Gaeta M, et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol. 2012 Dec;188(6):2046-54.Full text Abstract
130. Lamm DL, Riggs DR, Shriver JS, et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 1994 Jan;151(1):21-6. Abstract
131. Nepple KG, Lightfoot AJ, Rosevear HM, et al. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010 Nov;184(5):1915-9. Abstract
132. Kwan ML, Garren B, Nielsen ME, et al. Lifestyle and nutritional modifiable factors in the prevention and treatment of bladder cancer. Urol Oncol. 2019 Jun;37(6):380-6.Full text Abstract
133. Lamm DL, Riggs DR, Shriver JS, et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 1994 Jan;151(1):21-6. Abstract
Use of this content is subject to our disclaimer